RankingsPricing
  1. US-listed companies
  2. REGENERON PHARMACEUTICALS, INC.
  3. Financials
  4. Capital expenditures

REGENERON PHARMACEUTICALS, INC.REGN

Market cap
$81.6B
P/E ratio
SummaryFinancials
Period EndCapital expenditures (Million USD)YoY (%)
Dec 31, 2024-756+5.19%
Dec 31, 2023-719+21.78%
Dec 31, 2022-590+6.92%
Dec 31, 2021-552-10.20%
Dec 31, 2020-615+43.06%
Dec 31, 2019-430+12.14%
Dec 31, 2018-383+40.52%
Dec 31, 2017-273-46.75%
Dec 31, 2016-512-24.49%
Dec 31, 2015-678+103.58%
Dec 31, 2014-333+113.02%
Dec 31, 2013-156+216.85%
Dec 31, 2012-49-13.77%
Dec 31, 2011-57-42.60%
Dec 31, 2010-100

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)